Corrected coronary opacification decrease from coronary computed tomography angiography: Validation with quantitative 13N-ammonia positron emission tomography.


Journal

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534

Informations de publication

Date de publication:
04 2019
Historique:
received: 25 03 2017
accepted: 07 06 2017
pubmed: 8 7 2017
medline: 20 8 2020
entrez: 8 7 2017
Statut: ppublish

Résumé

To assess the functional relevance of a coronary artery stenosis, corrected coronary opacification (CCO) decrease derived from coronary computed tomography angiography (CCTA) has been proposed. The present study aims at validating CCO decrease with quantitative 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI). This retrospective study consists of 39 patients who underwent hybrid CCTA/PET-MPI. From CCTA, attenuation in the coronary lumen was measured before and after a stenosis and corrected to the aorta to calculate CCO and its decrease. Relative flow reserve (RFR) was calculated by dividing the stress myocardial blood flow (MBF) of a vessel territory subtended by a stenotic coronary by the stress MBF of the reference territories without stenoses. RFR was abnormal in 11 vessel territories (27%). CCO decrease yielded a sensitivity, specificity, negative predictive value, positive predictive value, and accuracy for prediction of an abnormal RFR of 73%, 70%, 88%, 47%, and 70%, respectively. CCTA-derived CCO decrease has moderate diagnostic accuracy to predict an abnormal RFR in PET-MPI. However, its high negative predictive value to rule out functional relevance of a given lesion may confer clinical implications in the diagnostic work-up of patients with a coronary stenosis.

Sections du résumé

BACKGROUND
To assess the functional relevance of a coronary artery stenosis, corrected coronary opacification (CCO) decrease derived from coronary computed tomography angiography (CCTA) has been proposed. The present study aims at validating CCO decrease with quantitative 13N-ammonia positron emission tomography (PET) myocardial perfusion imaging (MPI).
METHODS AND RESULTS
This retrospective study consists of 39 patients who underwent hybrid CCTA/PET-MPI. From CCTA, attenuation in the coronary lumen was measured before and after a stenosis and corrected to the aorta to calculate CCO and its decrease. Relative flow reserve (RFR) was calculated by dividing the stress myocardial blood flow (MBF) of a vessel territory subtended by a stenotic coronary by the stress MBF of the reference territories without stenoses. RFR was abnormal in 11 vessel territories (27%). CCO decrease yielded a sensitivity, specificity, negative predictive value, positive predictive value, and accuracy for prediction of an abnormal RFR of 73%, 70%, 88%, 47%, and 70%, respectively.
CONCLUSIONS
CCTA-derived CCO decrease has moderate diagnostic accuracy to predict an abnormal RFR in PET-MPI. However, its high negative predictive value to rule out functional relevance of a given lesion may confer clinical implications in the diagnostic work-up of patients with a coronary stenosis.

Identifiants

pubmed: 28685251
doi: 10.1007/s12350-017-0980-2
pii: 10.1007/s12350-017-0980-2
doi:

Substances chimiques

Nitrogen Radioisotopes 0
Nitrogen-13 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

561-568

Commentaires et corrections

Type : CommentIn

Références

J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
pubmed: 19573732
Circ Cardiovasc Imaging. 2010 Mar;3(2):179-86
pubmed: 20044512
Eur Heart J Cardiovasc Imaging. 2016 Sep;17(9):951-60
pubmed: 26992419
J Am Coll Cardiol. 2014 Apr 1;63(12):1145-1155
pubmed: 24486266
Eur Heart J. 2015 Dec 14;36(47):3359-67
pubmed: 26330417
Eur Heart J. 2011 Jun;32(12):1465-71
pubmed: 21320906
J Am Coll Cardiol. 2010 Jul 13;56(3):177-84
pubmed: 20537493
Eur Heart J. 2015 Dec 14;36(47):3345
pubmed: 26261297
Circ Cardiovasc Imaging. 2016 Sep;9(9):
pubmed: 27609817
J Nucl Med. 2012 Aug;53(8):1230-4
pubmed: 22776752
N Engl J Med. 2015 Apr 2;372(14):1291-300
pubmed: 25773919
J Nucl Med. 2013 Jan;54(1):55-63
pubmed: 23232274
Eur Heart J. 2008 Dec;29(24):3037-42
pubmed: 18996954
Lancet. 2015 Jun 13;385(9985):2383-91
pubmed: 25788230
Circ Cardiovasc Imaging. 2015 Jan;8(1):
pubmed: 25596142
Eur J Radiol. 2015 Jan;84(1):92-99
pubmed: 25467226
Circulation. 1994 Mar;89(3):1013-22
pubmed: 8124786
Circ Cardiovasc Imaging. 2011 Nov;4(6):678-84
pubmed: 21926262
J Nucl Med. 2006 Sep;47(9):1420-6
pubmed: 16954548
Eur Heart J. 2008 Jan;29(2):191-7
pubmed: 18089704
Clin Res Cardiol. 2017 Feb;106(2):140-150
pubmed: 27599974
J Am Coll Cardiol. 2013 Oct 29;62(18):1639-1653
pubmed: 23954338
J Am Coll Cardiol. 2010 Jun 22;55(25):2816-21
pubmed: 20579537
J Nucl Med. 2007 May;48(5):696-703
pubmed: 17475956
N Engl J Med. 2009 Jan 15;360(3):213-24
pubmed: 19144937
Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):430-6
pubmed: 22143224
JACC Cardiovasc Imaging. 2016 Sep;9(9):1074-1083
pubmed: 27372017
JACC Cardiovasc Imaging. 2011 Nov;4(11):1149-57
pubmed: 22093264
Eur Heart J. 2014 Oct 1;35(37):2541-619
pubmed: 25173339
N Engl J Med. 2014 Sep 25;371(13):1208-17
pubmed: 25176289
Acad Radiol. 2016 Aug;23(8):1008-14
pubmed: 27174030
Eur J Radiol. 2015 Aug;84(8):1509-1515
pubmed: 26022519
Circulation. 2008 Mar 11;117(10):1283-91
pubmed: 18268144
Eur J Nucl Med Mol Imaging. 2010 Mar;37(3):522-7
pubmed: 19789871
Eur Heart J Cardiovasc Imaging. 2015 Aug;16(8):842-7
pubmed: 25914037
J Am Coll Cardiol. 2011 Mar 15;57(11):1280-8
pubmed: 21392642

Auteurs

Dominik C Benz (DC)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Christoph Gräni (C)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Paola Ferro (P)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Luis Neumeier (L)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Michael Messerli (M)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Mathias Possner (M)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Olivier F Clerc (OF)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Catherine Gebhard (C)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Oliver Gaemperli (O)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Aju P Pazhenkottil (AP)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Philipp A Kaufmann (PA)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland.

Ronny R Buechel (RR)

Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Ramistrasse 100, 8091, Zurich, Switzerland. ronny.buechel@usz.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH